

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Allen, et al.

Application No.: 09/737,687

Filed: 12/14/2000

Title: SALICYLAMIDES AS SERINE PROTEASE  
INHIBITORS

Attorney Docket No.: 218 US

Assistant Commissioner for Patents  
Washington, D.C. 20231

Group Art Unit: 1626

Examiner: WRIGHT, S.

RECEIVED  
CENTRAL FAX CENTER

MAR 14 2005

Reply

Dear Sir:

This reply is in response to the Office Action mailed on November 19, 2003, for which a response is due on February 19, 2004. Applicants request reconsideration of the Application in view of the following reasons. Under separate cover, the Applicants file a Petition to the Director under 37 C.F.R. § 1.181(a) (3) (2003) invoking the Director's supervisory authority.

Remarks

Status of the Claims.

Claims 1-31 are pending in the Application of which Claims 9 and 18-31 are withdrawn from consideration and Claims 1-8 and 10-17 are objected to as containing non-elected subject matter.

Procedural History.

In an Office Action mailed July 30, 2001, the Examiner required the Applicants to elect one of three groups drawn to compounds of Formula 1, classified in various classes and subclasses (hereinafter "Restriction Requirement I"). The Examiner further required that the Applicants elect a single disclosed species from within the elected group. In a Response dated October 12, 2001, the Applicants elected Group I the species found on page 66, line 8, of the specification, namely 3-hydroxy-naphthalene-2-carboxylic acid (6-guanidino-pyridin-3-yl)-amide. The Applicants traversed the election of species requirement to the extent that the Examiner intended that the non-elected species would be permanently withdrawn from